| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| 500mg | |||
| Other Sizes |
| Targets |
(+)-Bornyl acetate does not have a single well-defined pharmacological target; it is a monoterpene ester with diverse biological activities. It has been investigated for potential roles in respiratory health, pain relief, and stress reduction. It has antiviral, anti-stimulant, antidepressant, and stimulant bile flow properties. As a chiral building block, it is used for the synthesis of various compounds. Its biological effects are likely mediated through interactions with various receptors and signaling pathways.
|
|---|---|
| ln Vitro |
In vitro, (+)-bornyl acetate has a stronger inhibitory effect on root growth of Arabidopsis seedlings. It is a chemical constituent of some essential oils. Its activity is typically evaluated in plant models for its effects on growth and development. In mammalian systems, it has been investigated for respiratory health, pain relief, and stress reduction effects. However, specific IC50 values and detailed in vitro data are not extensively reported in the available literature.
|
| ln Vivo |
In vivo, (+)-bornyl acetate has been investigated for potential roles in respiratory health, pain relief, and stress reduction. It has antiviral, anti-stimulant, antidepressant, and stimulant bile flow properties. As a component of essential oils, it is used in aromatherapy and traditional medicine. However, specific in vivo efficacy data, including dosing regimens and animal models, are not extensively detailed in the available literature. Further studies are needed to fully characterize its in vivo pharmacological profile.
|
| Enzyme Assay |
Cell-free assays for (+)-bornyl acetate involve characterizing its chemical properties and using it as a reference standard. Its identity and purity are confirmed by HPLC, NMR, and mass spectrometry. As a monoterpene ester, its physicochemical properties such as solubility and stability can be measured. The compound is typically handled as a liquid or crystals at room temperature. Detailed cell-free biological assay protocols are not extensively reported in the available literature.
|
| Cell Assay |
In vitro cellular assays for (+)-bornyl acetate would typically involve treating cells with various concentrations of the compound to study its effects on cell viability, inflammation, or other biological processes. However, specific assay protocols are not extensively documented in the available literature. The compound is typically dissolved in ethanol or DMSO and diluted in cell culture medium for in vitro studies. Its effects on respiratory cells, neuronal cells, or immune cells may be of interest.
|
| Animal Protocol |
In vivo animal studies for (+)-bornyl acetate are conducted in models of respiratory disease, pain, and stress. The compound is administered via various routes including oral gavage, inhalation, or topical application. Respiratory function, pain responses, and stress markers are assessed. However, specific dosing regimens and experimental protocols are not extensively documented in the available literature. Standard protocols for evaluating respiratory and analgesic agents would typically be employed.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of (+)-bornyl acetate include a molecular weight of 196.29 g/mol, molecular formula C12H20O2, and CAS No. 20347-65-3. It has a melting point of 29 °C. As a monoterpene ester, it is volatile and has good skin permeability. The compound is typically stored at appropriate conditions as a research reagent. Detailed ADME parameters such as half-life, Cmax, and AUC are not extensively reported in the available literature.
|
| Toxicity/Toxicokinetics |
The toxicity profile of (+)-bornyl acetate has not been extensively characterized in published literature. As a naturally occurring compound found in essential oils, it is generally considered to have a favorable safety profile at research doses. Standard safety precautions should be followed when handling this compound. It is intended for research use only and not for therapeutic applications in humans.
|
| References |
|
| Additional Infomation |
(+)-Borne acetate is a monoterpenoid compound belonging to the acetate class. Functionally, it is related to (+)-borneol. It has been reported to exist in Artemisia chamaemelifolia, Artemisia herba-alba, and other organisms with relevant data.
(+)-Bornyl acetate is a naturally occurring bicyclic monoterpene ester found in coniferous essential oils. It has been investigated for respiratory health, pain relief, and stress reduction. Its molecular formula is C12H20O2 with a molecular weight of 196.29 g/mol. (+)-Bornyl acetate is a research tool for studying monoterpene biology and essential oil pharmacology. It is not for therapeutic use. |
| Molecular Formula |
C12H20O2
|
|---|---|
| Molecular Weight |
196.2860
|
| Exact Mass |
196.146
|
| CAS # |
20347-65-3
|
| Related CAS # |
Bornyl acetate;76-49-3;(-)-Bornyl acetate;5655-61-8
|
| PubChem CID |
6950274
|
| Appearance |
Colorless to light yellow ointment
|
| Density |
1.0±0.1 g/cm3
|
| Boiling Point |
223.5±0.0 °C at 760 mmHg
|
| Flash Point |
87.4±6.0 °C
|
| Vapour Pressure |
0.1±0.4 mmHg at 25°C
|
| Index of Refraction |
1.480
|
| LogP |
3.6
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
14
|
| Complexity |
270
|
| Defined Atom Stereocenter Count |
3
|
| SMILES |
O(C(C([H])([H])[H])=O)[C@@]1([H])C([H])([H])C2([H])C([H])([H])C([H])([H])C1(C([H])([H])[H])C2(C([H])([H])[H])C([H])([H])[H]
|
| InChi Key |
KGEKLUUHTZCSIP-SCVCMEIPSA-N
|
| InChi Code |
InChI=1S/C12H20O2/c1-8(13)14-10-7-9-5-6-12(10,4)11(9,2)3/h9-10H,5-7H2,1-4H3/t9-,10+,12+/m1/s1
|
| Chemical Name |
[(1R,2S,4R)-1,7,7-trimethyl-2-bicyclo[2.2.1]heptanyl] acetate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.0945 mL | 25.4725 mL | 50.9450 mL | |
| 5 mM | 1.0189 mL | 5.0945 mL | 10.1890 mL | |
| 10 mM | 0.5095 mL | 2.5473 mL | 5.0945 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
